RESUMEN
The diagnosis of seronegative antiphospholipid syndrome (APS) has been proposed for patients with well-defined clinical APS but persistently negative for the routinely tested antiphospholipid antibodies (aPLs): antibodies to cardiolipin (aCL) and to ß(2) glycoprotein I (aß(2)GPI) and lupus anticoagulant (LA). Antibodies directed to phosphatidylethanolamine (aPE) have been described as the sole aPLs in some patients with clinical manifestations of APS. Here, we briefly summarize the available data on the clinical associations of aPEs and propose their investigation in patients with a clinical profile highly suggestive of seronegative APS.
Asunto(s)
Síndrome Antifosfolípido/diagnóstico , Fosfatidiletanolaminas/inmunología , Síndrome Antifosfolípido/sangre , Síndrome Antifosfolípido/inmunología , Autoanticuerpos/sangre , HumanosRESUMEN
Abstract: Current classification criteria for definite APS recommend the use of one or more of three positive standardized laboratory assays, including anticardiolipin antibodies (aCL), lupus anticoagulant (LA), and antibodies directed to ß(2)glycoprotein I (anti-ß(2)GPI) to detect antiphospholipid antibodies (aPL) in the presence of at least one of the two major clinical manifestations (i.e., thrombosis or pregnancy morbidity) of the syndrome. Several other autoantibodies shown to be directed to phospholipids and/or their complexes with phospholipids and/or to proteins of the coagulation cascade, as well as a mechanistic test for resistance to annexin A5 anticoagulant activity, have been proposed to be relevant to APS. A task force of worldwide scientists in the field discussed and analyzed critical questions related to 'non-criteria' aPL tests in an evidence-based manner during the 13th International Congress on Antiphospholipid Antibodies (APLA 2010, 13-16 April 2010, Galveston, Texas, USA). This report summarizes the findings, conclusions, and recommendations of this task force.
Asunto(s)
Comités Consultivos , Anticuerpos Antifosfolípidos/análisis , Síndrome Antifosfolípido/diagnóstico , Congresos como Asunto , Anticuerpos Antifosfolípidos/inmunología , Síndrome Antifosfolípido/inmunología , Pruebas Diagnósticas de Rutina/métodos , Pruebas Diagnósticas de Rutina/normas , Femenino , Guías como Asunto , Humanos , Embarazo , Protrombina/inmunología , TexasRESUMEN
The antiphospholipid antibodies included as laboratory criteria of the antiphospholipid syndrome (APS) are antibodies reacting with anionic phospholipids - anticardiolipin antibodies and lupus anticoagulant - and with beta(2)-glycoprotein I. However, antibodies reacting with phosphatidylethanolamine (aPE), a zwitterionic phospholipid, have also been described to be associated with the main features of APS. The objectives of this review are to describe the characteristics of aPE and to bring attention to recent evidence that aPE are correlated with the main clinical features of APS, notably, in the absence of the laboratory criteria of this syndrome.
Asunto(s)
Anticuerpos Antifosfolípidos/sangre , Síndrome Antifosfolípido/inmunología , Fosfatidiletanolaminas/inmunología , Aborto Habitual/etiología , Síndrome Antifosfolípido/complicaciones , Ensayo de Inmunoadsorción Enzimática , Humanos , Trombosis/etiologíaRESUMEN
The main objective of these meetings is to promote international collaboration in various clinical and research projects. This paper is the summary of the 2007 Ljubljana meeting, and offers an overview of the proposed projects. The technical and methodological details of the projects will be published on the forum's web site (http://www.med.ub.es/MIMMUN/FORUM/STUDIES.HTM).
Asunto(s)
Anticuerpos Anticardiolipina/metabolismo , Síndrome Antifosfolípido/fisiopatología , Animales , Síndrome Antifosfolípido/diagnóstico , Síndrome Antifosfolípido/terapia , Ensayos Clínicos como Asunto , Modelos Animales de Enfermedad , Humanos , Factores de RiesgoRESUMEN
The aim of this prospective study was to assess the prevalence of antiphospholipid antibodies (aPL) in women who had undergone in vitro fertilization (IVF) and the relationship between aPL and IVF outcome. A total of 101 infertile women with at least three unsuccessful IVF attempts were consecutively included in this study. Samples were collected in the follicular phase of a spontaneous ovarian cycle 2 months after the last ovulation induction treatment. Age-matched healthy fertile women (n = 160) were included as controls. All were evaluated for the presence of lupus anticoagulant (LA), antibodies (IgG, IgA, IgM) to cardiolipin (aCL), beta2-glycoprotein I (abeta2GPI), and phosphatidylethanolamine (aPE). Out of the 101 infertile women, 40 were persistently positive for aPL, showing a prevalence significantly higher than in controls (39.6% versus 5%, P < 0.0001). Among aPL, aPE were found with a significantly higher prevalence compared with LA, aCL, and aP2GPI (67.5% versus 0%, 15%, and 40%, respectively). Interestingly, aPE were found in 70% of the cases in the absence of the other aPL. The predominant isotype of aPL was IgA, in particular for abeta2GPI. Finally, no significant association was found between the presence of aPL and IVF outcome. This prospective study shows aPE as the most prevalent aPL in infertile women and IgA as more common than IgG and IgM. However, our results do not support an association between aPL and IVF outcome.
Asunto(s)
Anticuerpos Antifosfolípidos/sangre , Autoanticuerpos/sangre , Fertilización In Vitro , Infertilidad/sangre , Adolescente , Adulto , Cardiolipinas/inmunología , Humanos , Inmunoglobulina A/sangre , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Infertilidad/etiología , Inhibidor de Coagulación del Lupus/inmunología , Fosfatidiletanolaminas/inmunología , Prevalencia , Resultado del Tratamiento , beta 2 Glicoproteína I/inmunologíaRESUMEN
Clinical manifestations of the antiphospholipid antibody syndrome (APS) have been recently related to the presence of phosphatidylethanolamine antibodies (aPE). However, it is well known that some molecules such as cryoglobulins, immunoglobulins that undergo a reversible precipitation at low temperatures, may interfere with biological assays. With this in view, we report the case of a patient with APS who was positive for both IgM aPE and type III cryoglobulinemia. Moreover, we show for this patient a potential implication of aPE in the cryoprecipitate formation. To further analyze the potential association between cryoglobulins and aPE, and also the possible consequences for aPE assay, we selected 55 patients according to positivity for both IgM aPE and cryoglobulinemia. Determination of IgM aPE levels was made before and after removal of cryoprecipitate from the serum. Of the 55 selected patients, 52 (95%) presented no significant difference for IgM aPE levels before and after cryoprecipitation. These results were ascertained whatever the aPE levels and clinical status of the patient. Taken together, our results indicate that cryoprecipitation does not interfere in most cases (95%) with the dosage of IgM aPE. Thus, IgM aPE do not appear to be involved in the formation of the cryoprecipitate.
Asunto(s)
Anticuerpos Antifosfolípidos/análisis , Crioglobulinas/análisis , Ensayo de Inmunoadsorción Enzimática/métodos , Inmunoglobulina M/sangre , Adulto , Anticoagulantes/uso terapéutico , Síndrome Antifosfolípido/diagnóstico , Síndrome Antifosfolípido/tratamiento farmacológico , Estudios de Cohortes , Crioglobulinas/clasificación , Femenino , Humanos , Inmunoglobulina M/inmunología , Masculino , Fenindiona/análogos & derivados , Fenindiona/uso terapéutico , Resultado del TratamientoRESUMEN
According to international criteria, autoimmune hepatitis (AIH) type 1 is characterized by the presence of antinuclear or anti-smooth muscle antibodies (SMA) with F-actin specificity. SMA have been found in 85% of AIH patients, but are not specific to this disease, and anti-F-actin specificity is not always verified when SMA are detected. The objective of this study was to determine the diagnostic value of anti-F-actin antibodies in a large population. A multicenter study involving 12 clinical centers was performed. Patients were selected on the basis of the presence of F-actin SMA detected by indirect immunofluorescence (IIF) on rat liver-kidney-stomach sections and was confirmed by IIF on Hep2 cells treated with colchicine, or F-actin dot-blot. The clinical status of patients was determined from their medical records. One hundred sixty-eight patients were included: 76% women, 24% men; mean age of 45 years (range, 2-88 years), with a bimodal age distribution. Sixty percent had AIH type 1, and 40% had another disease. In the group of women younger than 25 years, 90% had AIH type 1. Other pathologies associated with antiactin were other liver diseases (19%), including viral hepatitis C (7%), and non-liver diseases (21%), including connective tissue diseases (12%). Antibody titers were higher in AIH than in other diseases. Antiactin antibodies are of major diagnostic value in AIH, especially in young women; they may be found in other disease settings, but mostly at low levels.
Asunto(s)
Actinas/inmunología , Anticuerpos Antinucleares/inmunología , Estudios Multicéntricos como Asunto , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Animales , Línea Celular Tumoral , Distribución de Chi-Cuadrado , Niño , Preescolar , Colchicina/farmacología , Enfermedades del Tejido Conjuntivo/diagnóstico , Enfermedades del Tejido Conjuntivo/inmunología , Femenino , Técnica del Anticuerpo Fluorescente Indirecta , Francia , Hepatitis C/inmunología , Hepatitis Autoinmune/inmunología , Hepatitis Autoinmune/patología , Humanos , Masculino , Persona de Mediana Edad , Músculo Liso/inmunología , Ratas , Estudios RetrospectivosRESUMEN
Two-hundred ninety five patients with the antiphospholipid syndrome (APS) were studied for the presence of antibodies against six anti-beta2GPI-related peptides Abs. The prevalence of a wide spectrum of clinical and laboratory parameters of APS was evaluated in all patients, and correlated with the presence of each anti-beta2GPI peptide antibody. The rates of the various antipeptides Abs ranged from 18.0 to 63.7%. Altogether, 87.1% of the patients had antibody reactivity against at least one of the six beta2GPI-related peptides. A high degree of simultaneous reactivity against several beta2GPI-peptides was found. Positive and negative correlations were found between several antipeptides Abs and the rates of thrombosis and fetal loss. Our results point to a heterogeneous activity of antiphospholipid Abs in APS patients, directed, often concurrently, against various epitopes of the beta2GPI molecule. Evaluation of APS patients for the presence of specific antipeptides Abs may be of a value in predicting the risk for future thrombotic and obstetrical complication, as well as for specific therapeutic purposes.
Asunto(s)
Anticuerpos/inmunología , Síndrome Antifosfolípido/inmunología , Glicoproteínas/inmunología , Péptidos/química , Péptidos/inmunología , Adolescente , Adulto , Secuencia de Aminoácidos , Síndrome Antifosfolípido/etiología , Glicoproteínas/química , Humanos , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/inmunología , Persona de Mediana Edad , Datos de Secuencia Molecular , beta 2 Glicoproteína IRESUMEN
USEFULLNESS OF DETECTION OF ANTIBODIES AGAINST THE ACETYLCHOLINE RECEPTOR IN THE DIAGNOSIS OF MYASTHENIA GRAVIS (MG): MG is an autoimmune disorder including a fatigability of skeletal muscles and the presence of antibodies against the acetylcholine receptor (AChRAbs). These Abs are pathogenic by blocking the acetylcholine receptor within the neuromuscular junction. A transient neonatal MG occurs in 12% of babies born to myasthenic mothers. AChRAbs have been found in 77 to 89% of systemic MG and in 47 to 60% in ocular form of MG. These Abs are generally directed against the "Main Immunogenic Region" (MIR) within the a subunit of the receptor; others are directed against beta, gamma and epsilon subunits. Eleven to 23% of the MG are negative for the Abs directed against the a subunit reinforcing the interest to detect the other AChRAbs, specially the anti-epsilon subunit Abs and the Abs directed against the muscle-specific receptor tyrosine kinase. MULTICENTER EVALUATION: In order to compare the results of AChRAbs for a same patient from various laboratories, a multicenter study was performed on 26 sera with different titers of AChRAbs using radioimmunoassays. Six french laboratories have participated to this study. The antigen was obtained from TE671 cells for 5 laboratories (3 used a commercial test) or from human muscle (1 laboratory). At the end of the study, the qualitative analysis of the results showed a concordance of 92.3%. The interpretation of AChRAbs assays can thus be done by clinicians whatever the test is used. A same quality control is nowadays used by the six laboratories in order to estimate quantitative results according to the assay performed. USEFULNESS OF THE OTHER ABS: The Abs directed against the striated muscle are good markers of thymoma in MG but are not specific for MG. The Abs directed against titin which is the major target of the anti-striated muscle Abs, are also good biological markers of thymoma specially in MG adults younger than 60 years. The detection of anti-myoid cells and thymic reticuloepithelial cells Abs is no more useful due to a lower sensitivity compared to the Abs directed against the striated muscle.
Asunto(s)
Autoanticuerpos/análisis , Miastenia Gravis/diagnóstico , Miastenia Gravis/inmunología , Receptores Colinérgicos/inmunología , Autoanticuerpos/inmunología , Biomarcadores/análisis , Humanos , Variaciones Dependientes del Observador , Control de Calidad , Radioinmunoensayo , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
Despite the widely recognized practical importance of anticardiolipin (aCL) ELISA, the reliability of this test has been recently discussed. In order to investigate this area on European scale, we sent to 30 experienced centers a questionnaire focusing on the diagnostic procedures applied to patients with antiphospholipid syndrome (APS) and on the detailed protocols used to perform aCL. Anticardiolipin ELISA was found to be the most frequently performed test in patients with suspected APS, but significant difference was shown among the various protocols. The cross-laboratory multiple examination of ten serum samples evaluated independently by the 24 centers pointed out the difficulty in getting comparable results. Therefore a "consensus" protocol was derived from the aCL methods giving the best performance. The materials and reagents necessary to perform the "consensus" method, including, as putative standards, one IgG and one IgM monoclonal antibody (HCAL and EY2C9) were distributed to 19 Centers. The results of one IgG and one IgM aCL high positive sera measured in serial dilutions were compared. A progressive decrease in the variability of the values obtained for a given sample appeared evident when all the laboratories used the same standard, in their own in-house ELISA and even more in the "consensus" ELISA. Our data show that aCL ELISA standardization is necessary in order to obtain comparable results in different laboratories.
Asunto(s)
Anticuerpos Anticardiolipina/sangre , Adulto , Anticuerpos Monoclonales , Síndrome Antifosfolípido/diagnóstico , Recolección de Datos , Toma de Decisiones , Ensayo de Inmunoadsorción Enzimática/métodos , Ensayo de Inmunoadsorción Enzimática/normas , Femenino , Humanos , Inmunoglobulina G , Inmunoglobulina M , Masculino , Persona de Mediana Edad , Variaciones Dependientes del Observador , Estándares de Referencia , Reproducibilidad de los ResultadosRESUMEN
The objective of this study was to assess the interest of antiphosphatidylethanolamine antibodies (aPE) in unexplained thrombosis (UT) defined as thrombotic episode without any of the main autoimmune and hereditary thrombophilic defects. Results from 98 UT were compared to those of (I) 142 patients with thrombophilia: 67 antiphospholipid syndrome (APS) and 75 hereditary hemostatic defects (HHD); (II) 110 patients without thrombosis: 60 with systemic lupus erythematosus (SLE) and 50 with infectious diseases (ID). As compared to controls (100 blood donors), aPE prevalence was significantly higher in both autoimmune contexts (APS: 43%; SLE: 40%, p<0.0001) and among non-autoimmune pathologies, only in UT (18%, p = 0.001) conversely to HHD (8%) or ID (10%). aPE prevalence in UT was not statistically different from that found in Primary APS (32%, p = 0.076) but lower than in Secondary APS (65%, p <0.005). In UT, aPE were mainly of IgM isotype like in Primary APS and they were found alone whereas in SLE they were always associated with classical antiphospholipid antibodies. No significant association was found between any isotype of aPE and a site of thrombosis in UT as well as in APS. In conclusion, this study demonstrates an increase of the prevalence of aPE in patients with unexplained thrombosis. Thus, aPE investigation appears to be of interest in UT and their persistent presence could define a biological variant of APS.
Asunto(s)
Anticuerpos Antifosfolípidos/sangre , Autoanticuerpos/sangre , Fosfatidiletanolaminas/inmunología , Trombosis/epidemiología , Adulto , Síndrome Antifosfolípido/sangre , Síndrome Antifosfolípido/inmunología , Femenino , Francia/epidemiología , Humanos , Isotipos de Inmunoglobulinas/sangre , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/inmunología , Masculino , Persona de Mediana Edad , Prevalencia , Trombofilia/sangre , Trombofilia/inmunología , Trombosis/etiología , Trombosis/inmunologíaRESUMEN
The term "antiphospholipids" (aPLs) refers to an heterogeneous family of antibodies diagnosed either by clotting tests: the lupus anticoagulants or by Elisa: anticardiolipin (aCL) and anti-beta2-glycoprotein I (anti-beta2GP1) especially. aPLS recognize phospholipids, alone or bound to plasma protein cofactor(s), or the cofactors themselves. aPLs have long been described in autoimmune diseases such as SLE, but may also be found in other clinical settings including infections, malignancies and drug administration. Their persistent presence can be associated with venous and/or arterial thrombotic complications and/or recurrent miscarriage, thus defining the "antiphospholipid syndrome" (APS). The heterogeneity of aPLs makes a comprehensive approach to laboratory investigation essential. Detection of lupus anticoagulants relies on increased clotting times in phospholipid-dependent tests. Their 4 step diagnosis includes: 1) screening (by at least two different tests); 2) demonstration of an inhibitory activity; 3) evidence of its phospholipid dependence; 4) exclusion of an associated coagulopathy. Among the aPLs detected by Elisa, IgG aCL are the most frequently investigated. However, other antibodies may represent useful biological tools. Among them, anti-beta2GP1 are thought to be more closely associated with a history of thrombosis than aCL and testing for anti-beta2 GP1 should now be systematically included in the biological diagnosis of APS. The Elisa used for aCL and anti-beta2GP1 are not fully standardized, and a number of methodological parameters may account for the interlaboratory discrepancies often observed. The clinical importance of other antibodies such as antiphosphatidylethanolamine, antiprothrombin or antiannexin V is being evaluated. An appropriate laboratory investigation of APS should, in all cases, combine the use of clotting and immunological assays, and assess the persistence of autoantibodies over time.
Asunto(s)
Anticuerpos Antifosfolípidos , Síndrome Antifosfolípido/diagnóstico , Lupus Eritematoso Sistémico/inmunología , Trombosis/inmunología , Adulto , Anexina A5/inmunología , Anticuerpos Anticardiolipina/análisis , Anticuerpos Anticardiolipina/inmunología , Anticuerpos Antifosfolípidos/análisis , Anticuerpos Antifosfolípidos/inmunología , Anticoagulantes/inmunología , Síndrome Antifosfolípido/inmunología , Apolipoproteínas/inmunología , Pruebas de Coagulación Sanguínea , Ensayo de Inmunoadsorción Enzimática , Femenino , Glicoproteínas/inmunología , Humanos , Inhibidor de Coagulación del Lupus/análisis , Inhibidor de Coagulación del Lupus/inmunología , Lupus Eritematoso Sistémico/diagnóstico , Masculino , Glicoproteínas de Membrana/inmunología , Protrombina/antagonistas & inhibidores , Protrombina/inmunología , Trombosis/diagnóstico , beta 2 Glicoproteína IRESUMEN
Various antiphospholipid and/or antiprotein antibodies have been suspected to be associated with recurrent early foetal loss in absence of any habitual aetiology. We conducted a hospital-based case control study on women with no antecedent of thromboembolic or autoimmune disease. We studied 3 groups of 518 women: patients with unexplained primary recurrent early foetal loss, patients with explained episodes and mothers with no previous obstetrical accident. Matching the 3 groups was carried out on the basis of age, number or pregnancies and time elapsed since the end of the last pregnancy. Significant biological markers were then prospectively tested. The various antibodies were shown to be dependent on parity and on the presence of previous foetal loss: cut-off values were thus calculated using data obtained from the group of explained accidents, and adjusted for parity. Only anti-phosphatidylethanolamine IgM [odds ratio: 6.0, 95% confidence interval (2.3-15.7), p = 0.0003], anti-beta2-glycoprotein I IgG [4.4, (1.6-11.7), p = 0.0035] anti-annexin V IgG antibodies [3.2 (1.2-8.1), p = 0.015] and lupus anticoagulant [3.0, (1.3-6.8), p = 0.009], were found to be independent retrospective risk factors for unexplained early foetal loss. These four markers were subsequently found to be, during the following pregnancy, associated with a significant risk of foetal loss despite a low-dose aspirin treatment. In non-thrombotic, non-auto-immune women with unexplained primary recurrent early foetal loss, subgroups of patients with positive anti-phosphatidylethanolamine IgM antibodies, or positive anti-beta2-glycoprotein-I IgG antibodies, or positive anti-annexin V IgG antibodies or lupus anticoagulant must be particularised. This should allow therapeutic trials to be carried in well-defined patients.
Asunto(s)
Aborto Espontáneo/etiología , Síndrome Antifosfolípido/complicaciones , Proteínas/inmunología , Adolescente , Adulto , Anexina A5/inmunología , Anticuerpos Antifosfolípidos/efectos adversos , Anticuerpos Antifosfolípidos/sangre , Inhibidores Enzimáticos/inmunología , Femenino , Muerte Fetal/etiología , Muerte Fetal/inmunología , Glicoproteínas/inmunología , Humanos , Inmunoglobulina G/efectos adversos , Inmunoglobulina G/sangre , Inmunoglobulina M/efectos adversos , Inmunoglobulina M/sangre , Modelos Lineales , Inhibidor de Coagulación del Lupus/efectos adversos , Inhibidor de Coagulación del Lupus/sangre , Persona de Mediana Edad , Embarazo , Primer Trimestre del Embarazo , Segundo Trimestre del Embarazo , Estudios Retrospectivos , Factores de Riesgo , beta 2 Glicoproteína IRESUMEN
Microparticles (MPs) resulting from vesiculation of platelets and other blood cells have been extensively documented in vitro and have been found in increased numbers in several vascular diseases, but little is known about MPs of endothelial origin. The aim of this study was to analyze morphological, immunological, and functional characteristics of MPs derived from human umbilical vein endothelial cells (HUVECs) stimulated by TNF, and to investigate whether these MPs are detectable in healthy individuals and in patients with a prothrombotic coagulation abnormality. Electron microscopy evidenced bleb formation on the membrane of TNF-stimulated HUVECs, leading to increased numbers of MPs released in the supernatant. These endothelial microparticles (EMPs) expressed the same antigenic determinants as the corresponding cell surface, both in resting and activated conditions. MPs derived from TNF-stimulated cells induced coagulation in vitro, via a tissue factor/factor VII-dependent pathway. The expression of E-selectin, ICAM-1, alphavbeta3, and PECAM-1 suggests that MPs have an adhesion potential in addition to their procoagulant activity. In patients, labeling with alphavbeta3 was selected to discriminate EMPs from those of other origins. We provide evidence that endothelial-derived MPs are detectable in normal human blood and are increased in patients with a coagulation abnormality characterized by the presence of lupus anticoagulant. Thus, MPs can be induced by TNF in vitro, and may participate in vivo in the dissemination of proadhesive and procoagulant activities in thrombotic disorders.
Asunto(s)
Síndrome Antifosfolípido/sangre , Enfermedades Autoinmunes/sangre , Endotelio Vascular/ultraestructura , Inhibidor de Coagulación del Lupus/sangre , Lupus Eritematoso Sistémico/sangre , Trombofilia/etiología , Moléculas de Adhesión Celular/análisis , Células Cultivadas , Endotelio Vascular/efectos de los fármacos , Factor VII/fisiología , Citometría de Flujo , Humanos , Infecciones/sangre , Microscopía Confocal , Neoplasias/sangre , Receptores de Vitronectina/fisiología , Trombofilia/sangre , Tromboplastina/metabolismo , Factor de Necrosis Tumoral alfa/farmacología , Venas UmbilicalesAsunto(s)
Autoanticuerpos/análisis , Diabetes Mellitus Tipo 1/inmunología , Sistemas de Infusión de Insulina/efectos adversos , Insulina/inmunología , Adulto , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Femenino , Humanos , Bombas de Infusión Implantables , Insulina/administración & dosificación , Insulina/uso terapéutico , Masculino , Persona de Mediana EdadAsunto(s)
Síndrome Antifosfolípido/complicaciones , Hepatitis C Crónica/complicaciones , Adulto , Alanina Transaminasa/sangre , Anticuerpos Anticardiolipina/sangre , Síndrome Antifosfolípido/patología , Ensayo de Inmunoadsorción Enzimática , Glicoproteínas/sangre , Glicoproteínas/inmunología , Hepacivirus/genética , Hepacivirus/aislamiento & purificación , Hepatitis C Crónica/patología , Humanos , Masculino , ARN Viral/análisis , ARN Viral/inmunología , beta 2 Glicoproteína IRESUMEN
To investigate the prevalence, significance, and specificity of IgG isotype anti-beta 2-Glycoprotein I antibodies (a-beta 2-GPI) in antiphospholipid syndrome (APS), we developed an enzyme-linked immunosorbent assay (ELISA) for the detection of IgG-a-beta 2-GPI and tested sera from 61 patients with autoimmune disorders (AID), 39 patients with APS and 22 patients with systemic lupus erythematosus without APS, 139 patients with various infectious diseases (hepatitis C virus infection, human immunodeficiency virus infection, Q fever, Mediterranean spotted fever, syphilis) and 97 healthy control subjects. Using irradiated plates coated with human beta 2-GPI, we showed that in the sera of patients with AID, optical densities from the coated wells were significantly higher than those from the noncoated ones (p = 0.0001). In this assay, intra-assay and inter-assay variation coefficients ranged between 4% and 10%. Clinical evaluation showed that IgG-a-beta 2-GPI were found in 23 of 61 patients with AID but in only one patient with an infectious disease. The presence of the IgG-a-beta 2-GPI in association with APS (p = 0.005) was statistically significant with high specificity (98%) and positive predictive value (87.5%) but with low sensitivity (54%), and was significantly associated with venous thrombosis (p = 0.0025). In addition, the IgG-a-beta 2-GPI levels were highly correlated with those of anticardiolipin antibodies (aCL) (p < 0.001). In contrast to a-beta 2-GPI, aCL were found with a high prevalence (40%) in patients with infectious diseases. Because of their high specificity, anti-beta 2-GPI antibodies appear to be useful tools in the evaluation of the risk of APS. However, because of their low sensitivity, their detection needs to be associated with that of aCL.